Original Research

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, Kim J, Yoo S, Chung YT, Lee JM, Cho DY

Drug Design, Development and Therapy 2019, 13:1011-1022

Published Date: 29 March 2019